Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with by Ajore, Ram et al.
Research Article
Deletion of ribosomal protein genes is a common
vulnerability in human cancer, especially in concert
with TP53 mutations
Ram Ajore1,†, David Raiser2,†, Marie McConkey2, Magnus Jöud1, Bernd Boidol2, Brenton Mar2,
Gordon Saksena3, David M Weinstock4, Scott Armstrong5, Steven R Ellis6, Benjamin L Ebert2,3,*,‡ &
Björn Nilsson1,3,‡,**
Abstract
Heterozygous inactivating mutations in ribosomal protein genes
(RPGs) are associated with hematopoietic and developmental
abnormalities, activation of p53, and altered risk of cancer in
humans and model organisms. Here we performed a large-scale
analysis of cancer genome data to examine the frequency and
selective pressure of RPG lesions across human cancers. We found
that hemizygous RPG deletions are common, occurring in about
43% of 10,744 cancer specimens and cell lines. Consistent with
p53-dependent negative selection, such lesions are underrepre-
sented in TP53-intact tumors (P  1010), and shRNA-mediated
knockdown of RPGs activated p53 in TP53-wild-type cells. In
contrast, we did not see negative selection of RPG deletions in
TP53-mutant tumors. RPGs are conserved with respect to homozy-
gous deletions, and shRNA screening data from 174 cell lines
demonstrate that further suppression of hemizygously
deleted RPGs inhibits cell growth. Our results establish RPG
haploinsufficiency as a strikingly common vulnerability of human
cancers that associates with TP53 mutations and could be
targetable therapeutically.
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Introduction
The human ribosome consists of an rRNA scaffold and about 80
proteins, divided into two subunits. Ribosomal protein genes (RPGs)
are denoted RPS1, RPS2, etc. for the small (40S) subunit; RPL1,
RPL2, etc. for the large (60S) subunit.
Several recent lines of evidence hold that mutation of RPGs leads
to specific clinical and cellular phenotypes. Germline heterozygous
inactivating mutations or deletions in RPS19 and at least eight other
RPGs cause Diamond-Blackfan anemia (DBA), a disorder character-
ized by macrocytic anemia and cancer predisposition, and the
founding member of a class of disorders known as ribosomopathies
(Draptchinskaia et al, 1999; Gazda et al, 2006, 2008, 2012; Farrar
et al, 2008; Narla & Ebert, 2010; Vlachos et al, 2012; Raiser et al,
2014). Acquired somatic mutations in specific RPGs associate with
certain malignancies, including the 5q- subtype of myelodysplastic
syndrome (hemizygous deletions of RPS14; Ebert et al, 2008), T-cell
acute lymphoblastic leukemia (mutations in RPL5, RPL10, and
RPL22; Rao et al, 2012; De Keersmaecker et al, 2013), and
microsatellite-unstable endometrial and gastric cancer (mutations in
RPL22; Nagarajan et al, 2012; Novetsky et al, 2013). Eleven RPGs
are tumor suppressor genes in zebrafish, where hemizygous inacti-
vation of these genes causes malignant peripheral nerve sheath
tumors with high penetrance (Amsterdam et al, 2004; MacInnes
et al, 2008; Lai et al, 2009). In mouse models, RPG haploinsuffi-
ciency alters stem cell quiescence (Signer et al, 2014), homeobox
gene translation, and tissue patterning (Kondrashov et al, 2011; Xue
et al, 2015).
Despite these observations, the occurrence of RPG lesions in
human cancers has not been investigated systematically. We there-
fore carried out a large-scale analysis of cancer genome data to
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determine the frequency and selective pressure of RPG lesions
across human cancers. We first looked for chromosomal deletions
and amplifications and point mutations in RPGs using pre-existing
DNA copy number microarray and whole-exome sequencing data
from a total of 10,744 cancer specimens and cell lines. Because
recent studies have shown that RPG haploinsufficiency activates
p53 in ribosomopathies (Narla & Ebert, 2010; Raiser et al, 2014)
and the pathobiology of ribosomopathies can be alleviated by p53
inhibition (Volarevic et al, 2000; Sulic et al, 2005; Fumagalli et al,
2009; Barlow et al, 2010; Dutt et al, 2011; Jaako et al, 2011), we
hypothesized that inactivation of RPGs could lead to negative selec-
tion unless the cells have mutated TP53, and, accordingly, looked
for associations between inactivating RPG lesions and TP53 muta-
tion. While we observed few point mutations and homozygous dele-
tions in RPGs, we detected hemizygous RPG deletions in a large
proportion (43%) of samples. Consistent with negative selection,
further analyses revealed an underrepresentation of RPG deletions
in TP53-intact tumors, whereas we did not see any signs of negative
selection in TP53-mutant tumors. Furthermore, functional experi-
ments showed that deficiency of frequently deleted RPGs increases
p53 activity in TP53-intact cell lines and perturbs rRNA maturation
both in cell lines cultured ex vivo and in primary acute leukemia
cells with specific RPG deletions and expanded in vivo in xenograft
models. Finally, consistent with the low frequency of homozygous
deletion, analysis of genomewide shRNA screening data showed
that further suppression of hemizygously deleted RPGs inhibits the
growth of RPG-haploinsufficient cancer cells. We conclude that RPG
haploinsufficiency as a common feature of human cancers that asso-
ciates with TP53 mutations and could be targetable therapeutically.
Results
Haploinsufficiency for RPGs on the basis of hemizygous regional
deletions is a common feature of cancer genomes
We first analyzed DNA copy number profiles of 7,225 cancer speci-
mens belonging to 24 tumor types using data from The Cancer
Genome Atlas, TCGA (Cancer Genome Atlas Research Network
et al, 2013). Using log2 copy number ratio thresholds between 0.3
and 0.7 (median 0.5), we detected deletions affecting RPGs in
67–22% of specimens (median 43%), and in all tumor types
analyzed (Fig 1A and Table 1). In 58–12% (median 32%) of
tumors, we detected multiple RPG deletions (Fig 1C). Consistent
with negative selection, we observed lower deletion frequencies for
RPG than for other genes (Fig 1C and D). Validation in two indepen-
dent sets of copy number profiles of 2,476 specimens belonging to
13 tumor types from Tumorscape (Beroukhim et al, 2010) and
1,043 cancer cell lines from the Cancer Cell Line Encyclopedia
(CCLE; Barretina et al, 2012) identified the same RPGs as frequently
deleted (Figs 1B and EV1, and Table 1). In all three data sets, almost
all (97–100%) of RPG deletions had copy numbers consistent with
hemizygous loss (Fig 2A), and few RPGs showed recurrent homozy-
gous deletions (Table EV1). Throughout, RPGs were hit by regional
deletions covering multiple genes, and all frequently deleted RPGs
were co-deleted with well-known tumor suppressor genes, including
RPL26 on chromosome 17p, which is always co-deleted with TP53,
and RPS6 on chromosome 9p, which is always co-deleted with
CDKN2A. In addition to copy number changes, we examined the
spectrum of point mutations in RPGs using whole-exome sequenc-
ing data from 4,655 TCGA samples. In contrast to the high
frequency of hemizygous deletions, we found a low frequency of
point mutations in RPGs, although we noted recurrent mutations in
RPL5, RPL10, and RPL22 in several tumor types as reported previ-
ously (Nagarajan et al, 2012; Rao et al, 2012; De Keersmaecker
et al, 2013; Novetsky et al, 2013; Table EV2). In summary, these
data show that RPG haploinsufficiency on the basis of regional dele-
tions occurs in a large proportion of human cancers.
Deletion of RPGs in cancer cells is restricted by p53-dependent
negative selection
Recently, studies aimed at understanding the molecular mechanisms
of ribosomopathies have identified p53 as a central mediator of the
clinical features of these diseases (Narla & Ebert, 2010; Raiser et al,
2014). In both DBA and the 5q- syndrome, the hematopoietic pheno-
type is at least partly linked to p53 activation, and animal models
have confirmed p53 as a sensor of ribosome dysfunction (Volarevic
et al, 2000; Sulic et al, 2005; Fumagalli et al, 2009; Barlow et al,
2010; Dutt et al, 2011; Jaako et al, 2011). In normal cells, the
expression of RPGs is tightly coordinated. In DBA and the 5q-
syndrome, however, the RPG haploinsufficiency is thought to
perturb the stoichiometry of ribosomal proteins, leading to ineffi-
cient ribosome assembly and increased concentrations of free ribo-
somal proteins, some of which (RPL5 and RPL11) regulate key
components of the 5S ribonucleoprotein particle (Macias et al, 2010;
Donati et al, 2013; Sloan et al, 2013; Goudarzi & Lindstrom, 2016).
When ribosome biogenesis is blocked, the 5S SNP pre-ribosomal
complex is re-directed from assembly into 60S ribosomes to MDM2
E3 ubiquitin ligase inhibition, thereby inhibiting the ability of
MDM2 to target p53 for proteasomal degradation (Fumagalli et al,
2009; Zhang & Lu, 2009; Deisenroth & Zhang, 2010; Miliani de
Marval & Zhang, 2011; Zhou et al, 2013; Goudarzi & Lindstrom,
2016). Moreover, in vitro and in vivo studies support that the pheno-
typic effects of RPG haploinsufficiency can be alleviated by genetic
or pharmacological inhibition of p53 (Volarevic et al, 2000; Sulic
et al, 2005; Fumagalli et al, 2009; Barlow et al, 2010; Dutt et al,
2011; Jaako et al, 2011).
Because of these reports, we hypothesized that acquisition of
RPG deletions in cancer cells could lead to p53 activation and
thereby negative selection, unless the p53 pathway has been inacti-
vated. To test this hypothesis, we compared the copy number distri-
butions for RPGs versus other genes across 4,675 TCGA samples
having both copy number microarray and whole-exome sequence
data, enabling the detection of RPG deletions as well as deletions
and point mutations in TP53. We found an underrepresentation of
hemizygous RPG deletions in TP53-wild-type tumors (Wilcoxon
rank-sum P  1010), whereas RPGs and other genes showed iden-
tical copy number distributions in TP53-mutant tumors (Fig 2A).
Similarly, among TP53-wild-type tumors, but not among TP53-
mutant tumors, we found fewer cases with hemizygous deletions
affecting RPGs than with hemizygous deletions affecting random
gene sets of the same size (permutation testing P = 0.04 with 1,000
random sets of genes located on other autosomes than chromosome
17), whereas no difference was detected in TP53-mutant tumors.
Additionally, TP53-mutant tumors showed higher numbers of
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RPG deletions in total (Fig 2B), RPG deletions that could be detected
in TP53-wild-type tumors were enriched in tumors harboring
alternative p53 pathway-inactivating lesions, including MDM2
amplifications and CDKN2A deletions (Fig EV2). Taken together,
these results indicate that the p53 pathway restricts the acquisition
of RPG deletions in cancer cells.
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Figure 1. Hemizygous deletion of RPGs is a common feature of cancer genomes.
Given the evidence that RPG haploinsufficiency can alter cellular phenotypes and modulate oncogenesis, we performed a systematic examination of somatic alterations of
RPGs in cancer broadly.
A Deletion frequencies for different RPGs estimated from DNA copy number profiles of 7,275 primary cancer specimens belonging to 24 different tumor types (red).
B Analysis of DNA copy number profiles of 2,476 primary cancer specimens belonging to 13 tumor types (including four not represented in the TCGA) identified the
same RPGs as frequently deleted. Similar results were also calculated with DNA copy number profiles of 1,043 cancer cell lines (Fig EV1). The results shown were
obtained using log2 ratio 0.5 as threshold. Similar results were obtained with other reasonable thresholds.
C Histogram of number of deletions per tumor for RPGs and for 1,000 equally sized random gene sets in the TCGA samples. Tumors with multiple RPG deletions were
common. Consistent with negative selection, we also detected fewer deletions in RPGs than in 1,000 random gene sets of the same size. This plot was obtained with
a log2 threshold of 0.5, detecting both hemizygous and homozygous deletions.
D Corresponding plot obtained with the more conservative log2 threshold 2.0, primarily detecting homozygous deletions.
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Deletion of RPGs leads to loss of coordinated RPG expression and
p53 activation
Previous studies aimed at understanding the molecular mechanisms
of DBA and the 5q- syndrome have shown that decreased expres-
sion of specific RPGs (RPS6, RPS14, and RPS19) leads to p53 activa-
tion (Narla & Ebert, 2010; Raiser et al, 2014). However, the RPGs
we found to be deleted in human cancers have not been studied
functionally in this regard. To examine whether p53 senses
decreased expression of the frequently deleted RPGs, we used
shRNA-mediated knockdown in the TP53-wild-type lung adenocarci-
noma cell line A549 (Fumagalli et al, 2009; Dutt et al, 2011). For all
eight RPGs tested, multiple shRNAs caused elevated p53 protein
levels and increased P21 transcript levels (Figs 2C and D, and EV3,
and Table EV3). Similarly, knockdown of three of the most
frequently deleted RPGs in TP53-wild-type MOLM13 leukemia cells
caused elevated expression of p53 and four p53 target genes P21,
BAX, PUMA, and NOXA (Figs EV4 and EV5). Taken together, these
data indicate that p53 activation results not only from decreased
expression of the RPGs that are mutated in ribosomopathies, but
also from decreased expression of the RPGs that are frequently
deleted in cancer cells.
Since RPG haploinsufficiency is thought to activate p53 by
altering ribosomal protein stoichiometry (Fumagalli et al, 2009),
we tested for associations between RPG copy number anomalies
(RPG-CNAs) and altered RPG expression patterns using 4,919
TCGA samples having both DNA copy number microarray data
and global mRNA-sequencing data. We found a correlation
between copy number and expression for most individual RPGs
(Fig EV6A). Quantifying RPG co-expression by calculating correla-
tion coefficients for all pairs of RPGs, we detected less correlated
RPG expression in tumors with a high RPG-CNA burden
(Fig EV6B and C), whereas tumors with few RPG-CNAs showed
RPG co-expression patterns comparable to those observed in non-
cancerous tissues (Fig EV6D). These data indicate that RPG-CNAs
lead to uncoordinated RPG expression, which, together with the
shRNA knockdown data, provides a possible explanation for the
negative selection of RPG deletion observed in TP53-wild-type
tumors (Fig 2).
Deletion of RPGs in cancer cells with intact p53 function
We asked which RPG deletions are permissible in cancer cells with
intact p53 function. To this end, we specifically analyzed the 30 cell
lines from CCLE that are both TP53-wild-type and sensitive to the
p53-activating compound Nutlin-3 (IC50 < 8 lmol; Barretina et al,
2012; Sonkin et al, 2013), where the latter supports that p53 has not
been inactivated by alternative mutations in other genes. Interest-
ingly, the most recurrently deleted RPG in these cell lines was
RPL22 (Table EV4). Firstly, Rpl22/ knockout mice have only
subtle phenotypes with no significant translation defects, probably
because these mice show increased expression of the paralog Rpl22-
like1 (Rpl22 l1) which is incorporated in the ribosome instead of
Rps22 (O’Leary et al, 2013). Secondly, RPL22 has been identified as
a potential tumor suppressor gene that is mutated or deleted in
T-ALL and several epithelial tumor types (Rao et al, 2012; Novetsky
et al, 2013; Goudarzi & Lindstrom, 2016). Another interesting obser-
vation was recurrent deletion of RPS6, which (like in the primary
tumors) was always associated with co-deletion of CDKN2A. These
data indicate that some RPG deletions are less likely to cause nega-
tive selection, either because of gene redundancy, because they do
not activate p53, or because they are associated with a pro-prolifera-
tive effect that allows the cells to escape the negative effect of p53
activation.
Further suppression of deleted RPGs inhibits the proliferation of
cancer cells
The almost complete lack of homozygous RPG deletions in the three
copy number data sets supports that such lesions are not tolerated.
These observations are consistent with the notion that ribosomal
proteins are essential for generation of functional ribosomes and cell
survival. To investigate whether RPG haploinsufficiency renders
cancer cells vulnerable to further suppression of ribosome function,
we analyzed two sets of shRNA screening data from 102 and 72
genomically annotated cancer cell lines (Cheung et al, 2011;
Marcotte et al, 2012). These pooled screens targeted 11,194 and
16,056 genes, including 26 and 55 RPGs, respectively. For each
targeted gene, the effect of knockdown on proliferation in cell lines
Table 1. Ten most frequently deleted RPGs.
Gene Chr Start (bp) End (bp)
TCGA CCLE Tumorscape
n % n % n %
RPL26 17 8,280,833 8,286,565 1,752 24.2 340 32.6 310 12.5
RPL13 16 89,627,064 89,633,237 1,430 19.8 204 19.6 222 9.0
RPS6 9 19,376,253 19,380,235 1,411 19.5 373 35.8 269 10.9
RPL17 18 47,014,850 47,018,935 1,335 18.5 393 37.7 173 7.0
RPL29 3 52,027,643 52,029,958 1,283 17.8 340 32.6 229 9.2
RPL3 22 39,708,886 39,715,670 1,205 16.7 263 25.2 152 6.1
RPL14 3 40,498,782 40,503,863 1,133 15.7 292 28.0 209 8.4
RPSA 3 39,448,203 39,454,032 1,129 15.6 284 27.2 202 8.2
RPL21 13 27,825,691 27,830,702 1,121 15.5 328 31.4 224 9.0
RPS15 19 1,438,362 1,440,492 1,108 15.3 264 25.3 170 6.9
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carrying one gene copy, relative to the effect in cell lines carrying at
least two gene copies, was scored (Marcotte et al, 2012; Shao et al,
2013). In both data sets, we observed strongly significant enrich-
ments of negative gene scores among RPGs (P = 1.0 × 108 and
P = 1.7 × 104, respectively; Fig 3A and B), indicating that further
suppression of RPGs preferentially inhibits the growth of RPG-
haploinsufficient cells.
Deletion of RPGs influences rRNA maturation in cancer cells
Previously, in vitro studies have shown that knockdown of RPS6
and other 40S RPGs impairs the processing of pre-ribosomal RNA
species into mature rRNA in ribosomopathies(Narla & Ebert, 2010;
O’Donohue et al, 2010; Raiser et al, 2014). To explore whether RPG
haploinsufficiency leads to rRNA maturation defects also in cancer
cells, we decided to analyze rRNA maturation across pediatric acute
lymphoblastic leukemia (ALL) samples harboring CDKN2A (9p)
deletions with and without concurrent deletion of RPS6. Deletions
targeting CDKN2A are present in 20–30% of B-cell ALL and 95% of
T-cell ALL. We first genotyped 47 previously banked pediatric ALL
samples using copy number microarrays. For two samples (one with
homozygous deletion of CDKN2A but intact RPS6 and one with
homozygous deletion of CDKN2A and hemizygous deletion of
RPS6), we were able to obtain viable cells, which were xenografted
into NOD scid gamma immunodeficient mice and expanded in vivo.
RNA from sorted tumor cells was assessed by Northern blot to
analyze pre-ribosomal RNA processing. Interestingly, the RPS6-
haploinsufficient case exhibited rRNA maturation defects similar to
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Figure 2. RPG haploinsufficiency associates with TP53 mutation status and p53 activation.
A RPG deletions are underrepresented in TP53-intact tumors, but not in TP53-mutant tumors. Plots show cumulative copy number distributions for RPGs (blue)
versus all genes (dashed black) for 4,675 TCGA samples having both copy number microarray and whole-exome sequence data. However, cases without TP53
mutation/deletion show fewer copy numbers consistent with heterozygous loss of RPGs compared to other genes (brackets), whereas cases harboring TP53
mutations/deletions show no corresponding difference. These plots also show that, regardless of TP53 mutation status, homozygous loss of RPGs is extremely rare.
B Number of hemizygous RPG deletions in TP53-mutant and -wild-type tumors. Boxes indicate medians and the first and third quartiles. Whiskers indicate first and
third quartiles 1.5 times the interquartile range. Notches indicate confidence intervals around the median. P-values indicate significance by Wilcoxon rank-sum
test.
C, D To obtain further support for p53-negative selection, we used shRNA-mediated knockdown of RPGs in A549 cells, which are TP53-wild type. Panels show p53
protein levels as analyzed by Western blot (b-actin loading control), and P21 transcript levels as analyzed by qPCR (ACTB normalization control) after 4–6 days of
expression of two shRNAs per tested RPG. Error bars indicate standard deviation between triplicates. Throughout, we observed increased p53 levels and P21
expression. These data support that RPG deletions lead to p53 activation and negative selection in cancer cells.
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those seen previously in shRNA-targeted RPG-deficient cells (cf.
Narla & Ebert, 2010; Raiser et al, 2014 and references therein),
namely a reduction in 41S species (18S-E, 21S, and 41S) and an
accumulation of 30S species (30S and 45S), indicating that heterozy-
gous deletion of RPS6 impacts on ribosomal RNA biogenesis in ALL
cells (Fig 3C and D). The difference in rRNA pattern observed in
ALL cells with and without deletion of RPS6 was comparable to the
difference in rRNA pattern observed in TP53-wild-type MOLM13
leukemia cells with and without shRNA knockdown of RPS6
(Fig EV7). Collectively, these observations provide the first evidence
that the rRNA maturation defect that is observed in ribosomopathies
on the basis of heterozygous inactivating mutations in other RPGs
(Narla & Ebert, 2010; Raiser et al, 2014) may also be present in
cancer cells with hemizygous RPG deletions.
Discussion
Here we report the novel finding that ribosomal protein genes are
routinely deleted across human cancers, particularly in concert with
TP53 mutation. Such a finding could lead to new possibilities for
cancer therapy in TP53-mutant patients. Previously, mutation of
RPGs (without concurrent TP53 mutation) has primarily been asso-
ciated with rare ribosomopathies, specific tumor subtypes, and
cancer development in zebrafish models.
The analyses in this study are based on a large number of samples
from primary samples, belonging to a broad range of different cancer
types. The results indicate that RPG deletions are enriched among
the samples that have concurrent TP53 mutation. This finding is in
accordance with previous studies on ribosomopathies (particularly
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Figure 3. Consequences of hemizygous RPG deletions.
A, B To investigate whether RPG haploinsufficiency renders cancer cells susceptible to further suppression of ribosome function, we analyzed genomewide pooled
shRNA screening data from the (A) shARP and (B) Achilles studies (data for 72 and 102 genomically annotated cancer cell lines, respectively). For each targeted
gene, the effect of knockdown on proliferation in cell lines carrying one gene copy, relative to those carrying at least two gene copies, was scored. We observed
strongly significant enrichments of negative gene scores for RPGs (solid blue; P = 1.0 × 108 and P = 1.7 × 104, respectively) compared to other genes (gray),
demonstrating that further suppression of hemizygously deleted RPGs inhibits cell growth.
C, D (C) To explore whether RPG haploinsufficiency causes rRNA maturation defects in cancer cells, we focused on pediatric ALL with 9p deletions targeting CDKN2A.
From two previously banked samples (one with homozygous CDKN2A deletion but intact RPS6 and one with homozygous deletion of CDKN2A and hemizygous
deletion of RPS6), we obtained viable cells, which were xenografted into NOD scid gamma immunodeficient mice and expanded in vivo. RNA from sorted tumor
cells was assessed by Northern blot to analyze pre-ribosomal RNA processing. The RPS6-haploinsufficient case exhibited rRNA maturation defects similar to those
seen previously in shRNA-targeted RPS6-deficient cells, namely (D) a reduction in 41S species (18S-E, 21S and 41S) and an accumulation of 30S species (30S and
45S). These observations provide the first evidence indicating that the rRNA maturation defect that is observed in ribosomopathies may also be present in RPG-
haploinsufficient cancer cells.
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DBA and the 5q-syndrome) showing that RPG haploinsufficiency
leads to activation of the p53 pathway, most likely through the 5S
RNP-MDM2 pathway. One of the current main hypotheses is that the
ribosomal assembly intermediate 5S ribonucleoprotein particle,
containing RPL5, RPL11, and the 5S rRNA, accumulates when ribo-
some biogenesis is blocked; the excess 5S RNP binds to murine
double minute 2 (MDM2), the main p53-suppressor in the cell,
inhibiting its function and leading to p53 activation. Our data indi-
cate that targeted degradation of the mRNAs for RPGs that are
frequently deleted in cancer leads to p53 activation in A549 and
MOLM13 cells, implicating p53 activation and (secondary to that)
negative selection as a probable cause of the lower frequencies of
RPG deletions seen among TP53-wild-type tumors. Moving forward,
follow-up studies will be needed to examine whether this activation
is mediated through the 5S RNP-MDM2 pathway. Additionally, anal-
yses of clonal heterogeneity (e.g., using single-cell experiments or
mathematical modeling of allele ratios) could illuminate whether
p53 mutation precedes RPG deletion during oncogenesis.
Further, a central question about the biochemical consequences
of RPG haploinsufficiency will be to determine precisely how these
alterations affect rRNA maturation in cancer cells. Our data, though
limited in sample size, indicate that rRNA patterns in acute
lymphoblastic leukemia cells harboring RPS6 deletion are perturbed
in the same way as in cell lines with shRPS6 knockdown. These
observations motivate further studies with larger numbers of
samples to determine how variation in rRNA patterns associates
with genetics lesions in RPGs.
Finally, genes that are hemizygously deleted are not necessarily
drivers but can confer susceptibility for therapies (Muller et al,
2012; Nijhawan et al, 2012; Liu et al, 2015). Our study represents
the first detailed examination of vulnerabilities in a specific cellular
component. Our data show that RPG haploinsufficiency is a strik-
ingly common vulnerability that is enriched among p53-deficient
tumors, which are often hard to treat. Our results raise the question
whether it could be possible to exploit RPG haploinsufficiency to
selectively kill cancer cells. A number of drugs that modulate riboso-
mal function exist, including rapamycin and other inhibitors (“rapa-
logs”) of the mammalian target of rapamycin (mTOR; Easton &
Houghton, 2006), and compounds that inhibit ribosome biogenesis
by inhibiting rRNA synthesis (Drygin et al, 2011; Bywater et al,
2012; Peltonen et al, 2014; Colis et al, 2014). These drugs are active
against subsets of human tumors, but their therapeutic scope is
unknown and could depend on the presence of ribosome defects.
Future studies will inform how RPG deletions can be used for the
treatment of a large subset of human cancer.
Materials and Methods
Cancer genome data sets
Firstly, we obtained normalized, segmented Affymetrix and Agilent
DNA copy number data (downloadable.seg files) representing 7,225
primary tumor samples belonging to 24 tumor types from TCGA and
with matched whole-exome sequencing data (somatic mutations;
4,675 samples) and RNA-sequencing data (4,919 samples; Cancer
Genome Atlas Research Network et al, 2013; http://cancergenome.
nih.gov/). Gene-wise copy numbers by averaging the copy number
signal across genes (from annotated gene start to gene end) in each
sample. Secondly, we obtained corresponding data Affymetrix DNA
copy number data representing 2,476 primary tumor samples belong-
ing to 13 tumor types from Tumorscape (Beroukhim et al, 2010;
http://www.broadinstitute.org/tumorscape), and for 1,043 cancer
cell lines from the CCLE (Barretina et al, 2012; http://www.broad
institute.org/ccle). To determine whether a gene was deleted, we
applied log2 copy number thresholds between 0.3 and 0.7, corre-
sponding to linear scale copy numbers 1.6 and 1.2, respectively. A
log2 ratio of 0.7 corresponds to the theoretical copy number ampli-
tude for a hemizygous deletion that present in all tumor cells in a
sample with 80% tumor cell fraction (a TCGA inclusion criterion).
This threshold is conservative as it does not leave any room for
clonal heterogeneity, technical underestimation, or noise. The log2
ratio 0.3 corresponds to the midpoint between the theoretical copy
number and the euploid, and is less conservative. To call homo-
zygous deletions, we used a log2 ratio threshold of 2.0, correspond-
ing to copy number 0.5 in linear scale. For completeness, we
repeated our analyses with other reasonable thresholds, yielding
results in broad agreement with those shown. The file processing
and statistical analyses were done with Matlab (http://www.math
works.com), R (http://www.r-project.org), Ultrasome (Nilsson et al,
2009), RenderCat (Nilsson et al, 2007), and various scripts. The set
of RPGs was defined by the 78 annotated genes encoding the known
proteins of the small and large ribosomal subunits (Fig 1).
Lentiviral shRNA vectors and infection
Lentiviral shRNAs targeting frequently RPGs in the pLKO.1 or
pLKO_TRC005 vector were obtained from the The RNAi Consortium
(TRC) at the Broad Institute (Table EV3). Lentivirus was produced
in 293TL cells. A549 cells were infected with 1 day after plating in
the presence of 8 lg/ml polybrene (Sigma-Aldrich) and selected
24 h later with 2 lg/ml puromycin (Sigma-Aldrich) for at least 48 h
before collection and processing for protein lysates or mRNA. A549
cells were maintained at 37°C and 5% CO2 in F-12K medium
(ATCC) supplemented with 10% fetal bovine serum and 1% pen/
strep/glutamine (Gibco). MOLM13 cells were transduced by spinfec-
tion with 8 lg/ml polybrene (Sigma-Aldrich). The cells were
selected at 24 h after transduction with 0.3 lg/ml puromycin for
48 h. Puromycin-selected cells were harvested and divided as per
experimental need for processing RNA or protein lysate. MOLM13
cells were maintained in RPMI 1640 supplemented with 10% fetal
bovine serum and 1% PEST (Gibco).
Western blot
Cells for protein analysis were lysed with Pierce IP Lysis Buffer
(Thermo Scientific). Western blots were performed using 25–50 lg
of protein and primary antibodies against p53 (DO-1; Santa Cruz
Biotechnology) at 1:500 dilution and b-actin (C4; Santa Cruz
Biotechnology) at 1:3,000 dilution. HRP-conjugated anti-mouse
secondary antibody (GE Healthcare) was used at 1:10,000 dilution.
Immunoreactive proteins were visualized using SuperSignal West
Pico Chemiluminescence Substrate (Thermo Scientific). MOLM13
cells were lysed with Biorupter Pico (Diagenode) using 30/30 s on/
off for 10-min program in Laemmli sample buffer (Bio-Rad). Blots
were probed with primary antibody against p53 (Sc-126, DO-1,
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Santa Cruz Biotechnology) at 1:1,000 dilution and b-actin (Sc-8432,
C-1; Santa Cruz Biotechnology) at 1:3,000 dilution.
Quantitative real-time PCR
RNA was purified from A549 and MOLM13 cells using TRIzol (Invit-
rogen) and RNeasy mini kit (cat no 74104), respectively. First-strand
cDNA was generated using 100–200 ng of total RNA and oligo(dT)
primers with the Superscript III reverse transcription kit (Invitro-
gen), and Omniscript RT kit (cat no 205113) was used for cDNA
synthesis from MOLM13 cells. Quantitative RT–PCR was performed
using TaqMan Gene Expression Master Mix (Applied Biosystems)
or SYBR Green PCR Master Mix (Applied Biosystems) on an ABI
Prism 7900HT system and StepOnePlus Real-Time PCR system
(Applied Biosystems). We used TaqMan assays to assess the
knockdown effect for RPS6 (Hs01058685_g1), RPL26 (Hs0086
4008_m1), RPL13 (Hs00744303_s1), RPL21 (Hs03003806_g1),
RPL29 (Hs00426490_g1), RPL14 (Hs03004339_g1), RPSA (Hs0034
7791_s1), and RPS12 (Hs04184906_g1) using ACTB (ABI #401846)
as control, and P21 (Hs00355782_m1), NOXA (Hs00560402_m1),
PUMA (Hs00248075_m1), BAX (Hs00180269_m1) were assessed
using GAPDH (Hs02758991_g1) as endogenous control for MOLM13
cells. Quantitative PCR for P21 and ACTB was performed using
SYBR Green PCR Master Mix (Applied Biosystems) and the follow-
ing primers: P21 forward 50-GCTCTGCTGCAGGGGACAGC-30; P21
reverse 50-GCCGCCGTTTTCGACCCTGA-30; ACTB forward: 50-
AGCGAGCATCCCCCAAAGTT-30; and ACTB forward: 50-GGGCAC-
GAAGGCTCATCATT-30 for A549 cells.
Analysis of leukemia samples
We obtained DNA extracted from 47 blood and bone marrow
samples taken at diagnosis from patients with pediatric ALL. The
samples were collected and banked at the Dane Farber Cancer Insti-
tute subject to informed consent (Dana Farber Cancer Institute,
institutional review board protocol no. 05-001). The experiments
conformed to the principles set out in the WMA Declaration of
Helsinki [http://www.wma.net/en/30publications/10policies/b3/]
and the NIH Belmont Report [https://www.hhs.gov/ohrp/regula
tions-and-policy/belmont-report/]. The samples were analyzed on
Affymetrix 6.0 arrays (Affymetrix Inc.; data available for download
from the ArrayExpress repository accession no. E-MTAB-5450).
Copy number changes were delineated using the program Ultrasome
(Nilsson et al, 2009). We obtained banked tumor cells and
expanded them in vivo in NOD scid gamma immunodeficient mice
for about 6 months. When the mice appeared moribund, they were
sacrificed. Cells harvested from the spleens and bone marrow were
stained with anti-human CD45 (Miltenyi Biotec) and sorted by fluo-
rescence-activated cell sorting to purify tumor cells, from which
RNA was isolated for rRNA maturation analysis by Northern blot
(Qiagen kits). For Northern blot analysis, gel-fractionated RNA was
transferred to zeta-probe membranes (Bio-Rad). An oligonucleotide
probe 50-CCTCGCCCTCCGGGCTCCGTTAATGATC-30 (complemen-
tary to sequences 5520–5547 spanning the boundary between 18S
rRNA and ITS1) was labeled with 32P using T4 polynucleotide
kinase and hybridized overnight with membrane-bound RNA at
37°C in ULTRAHyb-Oligonucleotide hybridization buffer (Ambion).
Membranes were washed at 37°C with 6× SSC and subjected to
phosphorimager analysis. MOLM13 RPS6 knockdown RNA
samples were electrophoretically fractioned in MOPS-gel running
buffer (cat no AM8671, Ambion) and transferred to Biodyne nylon
membrane (cat no 77016, Thermo Scientific) using semi-dry blot
method. Hybridization and washing steps were followed as recom-
mended in Northern Max kit (AM1940, Thermo Scientific). The
biotinylated cDNA probe hybridization was visualized following
Chemiluminescent Nucleic Acid Detection Module (cat no 89880,
Thermo Scientific).
The paper explained
Problem
The human ribosome consists of an rRNA scaffold and about 80
proteins, divided into two subunits. Ribosomal protein genes (RPGs)
are denoted RPS1, RPS2, etc. for the small (40S) subunit; RPL1, RPL2,
etc. for the large (60S) subunit. Increasing evidence holds that muta-
tion of RPGs leads to specific clinical and cellular phenotypes, includ-
ing Diamond-Blackfan anemia, the 5q- subtype of myelodysplastic
syndrome, and specific tumor types. Furthermore, many RPGs are
tumor suppressor genes in animal models_ENREF_13. Despite these
observations, which support a link between RPG lesions and cancer,
the occurrence of RPG lesions in human cancers has not been investi-
gated systematically.
Results
We carried out a large-scale analysis of cancer genome data to deter-
mine the frequency and selective pressure of RPG lesions across
human cancers. We first looked for chromosomal deletions and ampli-
fications and point mutations in RPGs using pre-existing DNA copy
number microarray and whole-exome sequencing data from a total of
10,744 cancer specimens and cell lines. Because recent studies have
shown that RPG haploinsufficiency activates p53 in ribosomopathies,
and the pathobiology of ribosomopathies can be alleviated by p53
inhibition, we hypothesized inactivation of RPGs could lead to nega-
tive selection unless the cells have mutated TP53, and, accordingly,
looked for associations between inactivating RPG lesions and TP53
mutation. While we observed few point mutations and homozygous
deletions in RPGs, we detected hemizygous RPG deletions in about
43% of samples. Consistent with negative selection, further analyses
revealed an underrepresentation of RPG deletions in TP53-intact
tumors, whereas we did not see any signs of negative selection in
TP53-mutant tumors. Furthermore, functional experiments showed
that deficiency of frequently deleted RPGs increases p53 activity in
TP53-intact cell lines and perturbs rRNA maturation both in cell lines
cultured ex vivo and in primary acute leukemia cells with specific RPG
deletions and expanded in vivo in xenograft models. Finally, consistent
with the low frequency of homozygous deletion, analysis of genome-
wide shRNA screening data showed that further suppression of
hemizygously deleted RPGs inhibits the growth of RPG-haploinsuffi-
cient cancer cells.
Impact
Genes that are hemizygously deleted are not necessarily drivers but
can confer susceptibility for therapies. Our data show that RPG
haploinsufficiency is a strikingly common vulnerability that is enriched
among p53-deficient tumors, which are often hard to treat. Our
results raise the question whether it could be possible to exploit RPG
haploinsufficiency to selectively kill cancer cells. A number of drugs
that modulate ribosomal function exist. These drugs are active against
subsets of human tumors, but their therapeutic scope is unknown
and could depend on the presence of ribosome defects. Future studies
will inform how RPG deletions can be used for the treatment of a
large subset of human cancer.
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Analysis of shRNA screening data
To test whether further suppression of hemizygously deleted RPGs
inhibits cell growth, we used genomewide, pooled shRNA screening
data from the Achilles and shARP studies (Cheung et al, 2011;
Marcotte et al, 2012). The Achilles study provided data on 102 cell
lines infected with a pool of lentivirally delivered shRNAs,
composed of 54,020 shRNAs targeting 11,194 genes. The shARP
study provided data on 72 cancer cell lines infected with a pool of
78,432 shRNAs targeting 16,056 genes. Gene scores reflecting the
effect on knockdown on cell growth in cell lines carrying one copy
versus at least two copies were provided with the original publica-
tions (Cheung et al, 2011; Marcotte et al, 2012; Shao et al, 2013).
To test for enrichment of negative scores (indicating depletion)
among RPGs compared to other genes, we used RenderCat (Nilsson
et al, 2007).
Expanded View for this article is available online.
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